August 23, 2023
Exclusive: Bloomberg Technology’s Ed Ludlow Interviews Cellares’ CEO and Co-founder, Fabian Gerlinghaus on Company’s Massive $255M Series C Up-Round
Related News
-
![Cellares and GenomeFrontier Therapeutics Partner to Evaluate Automated Manufacturing for GF-CART01 on the Cell Shuttle<sup src=]()
® Platform">
September 16, 2026Cellares and GenomeFrontier Therapeutics Partner to Evaluate Automated Manufacturing for GF-CART01 on the Cell Shuttle® Platform
-
July 21, 2026Cellares and Papillon Therapeutics Partner to Automate Manufacturing of PPL-001 for Patients With Friedreich’s Ataxia
-
July 13, 2026
Cellares and Sonoma Biotherapeutics Collaborate to Automate Manufacturing of SBT-77-7101 Engineered Treg Cell Therapy on the Cell Shuttle® Platform
® Platform">
